

1 ***Pappa2* deletion has sex- and age-specific effects on bone in mice**

2 Julian K. Christians^{a,*}, Neilab Amiri^a, John D. Schipilow^b, Steven W. Zhang^a and Kristyna I.

3 May-Rashke^a

4

5 ^aDepartment of Biological Sciences, Simon Fraser University, Burnaby, Canada

6 ^bCentre for High-Throughput Phenogenomics, Oral Biological and Medical Sciences, University

7 of British Columbia, Vancouver, Canada

8

9 * Corresponding author

10

11 Julian K. Christians: julian_christians@sfu.ca

12 Neilab Amiri: neilab.amiri@kpu.ca

13 John D. Schipilow: johnschipilow@gmail.com

14 Steven W. Zhang: steven.zhang1213@gmail.com

15 Kristyna May-Rashke: kimayras@sfu.ca

16

17

18 Running title: Effects of *Pappa2* deletion on bone in mice

19 **Abstract**

20 Objective

21 In humans, loss-of-function mutations in the gene encoding pregnancy-associated pregnancy
22 protein-A2 cause short stature and slightly reduced bone density. The goal of this study was to
23 determine the effects of *Pappa2* deletion on bone in mice.

24 Design

25 *Pappa2* deletion mice and littermate controls were culled at 10, 19 or 30 weeks of age and
26 femurs were analysed by micro-computed tomography. Serum markers of bone turnover and
27 insulin-like growth factor binding protein 5 (IGFBP-5), a proteolytic target of PAPP-A2, were
28 measured by ELISA.

29 Results

30 At 10 and 19 weeks of age, *Pappa2* deletion mice had slightly reduced trabecular parameters, but
31 by 19 weeks of age, female deletion mice had increased cortical tissue mineral density, and this
32 trait was increased by a small amount in deletion mice of both sexes at 30 weeks. Cortical area
33 fraction was increased in *Pappa2* deletion mice at all ages. Deletion of *Pappa2* increased
34 circulating IGFBP-5 levels and reduced markers of bone turnover (PINP and TRACP 5b).

35 Conclusions

36 PAPP-A2 contributes to the regulation of bone structure and mass in mice, likely through control
37 of IGFBP-5 levels. The net effect of changes in bone formation and resorption depend on sex
38 and age, and differ between trabecular and cortical bone.

39

40 **Keywords:** bone, insulin-like growth factor, IGF, insulin-like growth factor binding protein,
41 IGFBP, pappalysin, PAPP-A2

42 **Introduction**

43

44 Pregnancy-associated pregnancy protein-A2 (PAPP-A2) is a protease of insulin-like growth
45 factor binding proteins (IGFBPs) [1] and therefore contributes to the regulation of insulin-like
46 growth factor (IGF) availability [2]. Recently, loss-of-function mutations in the human *PAPPA2*
47 gene were found to cause short stature and slightly reduced bone density [3,4], and these
48 conditions were improved by treatment with IGF-I [5–7]. IGF-I is known to play important roles
49 in bone physiology [8–10] while IGFBP-5 is one of the most abundant IGFBPs in bone [11] and
50 is a target of PAPP-A2 [1]. IGFBP-5 influences bone mineral density (BMD) [12–14] by
51 regulating IGF availability as well as through IGF-independent effects [15,16].

52

53 Study of the mechanisms by which PAPP-A2 influences skeletal growth and BMD will
54 require animal models. In mice, postnatal skeletal growth is reduced by both constitutive and
55 bone-specific deletion of *Pappa2* [17,18]. However, no effect of *Pappa2* deletion on BMD,
56 measured by pQCT, was observed in 4 month old mice [19]. The goal of the present study was to
57 examine the effects of constitutive *Pappa2* deletion on BMD at a range of ages using micro-
58 computed tomography (micro-CT) to allow assessment of bone microarchitecture, and also to
59 examine effects on circulating markers of bone turnover.

60

61 **Methods**

62

63 *Mice*

64

65 All work was carried out in accordance with the guidelines of the Canadian Council on Animal
66 Care and was approved by the SFU University Animal Care Committee (protocols 945-09, 1035-
67 11 and 1188-11). Constitutive *Pappa2* deletion mice with a C57BL/6 background were
68 generated as previously described [17,20]. Mice were collected at 10, 19 or 30 weeks of age.
69 Peak BMD is achieved shortly before 19 weeks [21], but trabecular bone peaks around 6-8
70 weeks and declines thereafter [22]. Thus, 10 week mice have not yet achieved peak BMD but are
71 close to maximum trabecular bone, 19 week mice have achieved peak BMD and show some
72 trabecular bone loss, while 30 week mice have more bone loss and females are approaching
73 reproductive senescence [23]. To generate the cohort collected at 10 weeks of age, mice
74 heterozygous for the wild-type and deletion alleles (*Pappa2^{wt/KO}*) were paired to produce litters
75 in which all three genotypes were present, and *Pappa2^{wt/wt}* mice were used as controls for the
76 homozygous deletion mice. To generate the cohorts collected at 19 and 30 weeks of age, mice
77 heterozygous for the conditional (floxed) and deletion alleles (*Pappa2^{fl/KO}*) were paired to
78 produce litters in which all three genotypes were present, and *Pappa2^{fl/fl}* mice were used as
79 controls; we have previously shown that postnatal growth does not differ between *Pappa2^{fl/fl}* and
80 *Pappa2^{wt/wt}* mice [20]. Mice were genotyped by PCR using ear-clip tissue obtained at weaning,
81 as previously described [20].

82

83 *Micro-computed tomography*

84

85 Following sacrifice, mice were stored frozen at -20°C. Mice were later thawed, the skin and
86 internal organs were removed, and the carcasses were exposed to dermestid beetles for removal
87 of soft tissue. Femurs were measured using calipers and regions proportional to 5% of the total

88 length of bone were used to measure trabecular parameters (in the distal metaphysis) and cortical
89 characteristics (at the mid-shaft). Bones were scanned using micro-CT with an isotropic voxel
90 size of 7.4 μ m (Scanco Medical μ CT100, Switzerland; 70kVp, 114 μ A, 100 ms integration time).
91 For trabecular bone, the region of interest was proximal to the distal growth plate. The region of
92 interest for cortical bone was immediately distal to the third trochanter (where the cross-section
93 of the bone appears round/oval rather than the shape of a tear drop). Measures of trabecular bone
94 microarchitecture included bone volume within the region of interest (BV, mm³), total volume of
95 the region of interest (TV, mm³), bone volume fraction (BV/TV, %), trabecular number (Tb.N,
96 mm⁻¹), trabecular thickness (Tb.Th, μ m), and trabecular separation (Tb.Sp, mm) [24]. Measures
97 of cortical bone morphology included total cross-sectional area (Tt.Ar, mm²), cortical bone area
98 (Ct.Ar, mm²), cortical area fraction (Ct.Ar/Tt.Ar, %), average cortical thickness (Ct.Th, μ m),
99 cortical porosity (Ct.Po, %) and tissue mineral density (TMD, mg calcium hydroxyapatite
100 (HA)/cm³) [24].

101

102 *Serum PINP and TRACP 5b*

103

104 We used ELISA to measure serum levels of a marker of osteoblast activity (bone formation), N-
105 terminal propeptide of type I procollagen (PINP) (AC-33F1, IDS Immunodiagnostics), and a
106 marker of osteoclast number (bone resorption), tartrate-resistant acid phosphatase form 5b
107 (TRACP 5b) (SB-TR103, IDS Immunodiagnostics) in a subset of constitutive *Pappa2* deletion
108 females at 6 and 19 weeks of age. We also measured serum IGFBP-5 at 19 and 30 weeks by
109 ELISA (DY578, R&D Systems).

110

111 *Statistical analyses*

112

113 Data were analysed using general linear models (proc GLM, SAS, version 9.4) including effects
114 of genotype, sex and the sex*genotype interaction term to test for sex-specific effects [25].

115 Where the interaction was significant, differences between genotypes were tested within each

116 sex using the ESTIMATE statement (proc GLM). Since PINP and TRACP 5b were measured in

117 the same individuals at two different ages, these data were analysed by repeated measures

118 analyses (proc MIXED, SAS, Version 9.4). Values of PINP, TRACP 5b and IGFBP-5 were log-

119 transformed prior to analyses because the distributions were skewed, with a few large values.

120

121 **Results and Discussion**

122

123 Regions of interest were selected as a proportion of total bone length, and so were slightly

124 smaller in *Pappa2* deletion mice at all ages because their bones were shorter (Tables 1-3). At 10

125 weeks of age, there were no sex-specific effects of *Pappa2* deletion (no significant genotype*sex

126 interactions). *Pappa2* deletion increased cortical area fraction and reduced trabecular thickness

127 (Table 1). At 19 weeks of age, *Pappa2* deletion increased cortical area fraction, cortical

128 thickness, and cortical TMD in females only. In contrast, *Pappa2* deletion reduced trabecular

129 bone volume fraction in males but not females, and there was a marginally non-significant

130 reduction in trabecular thickness in both sexes (Table 2). At 30 weeks of age, there were no

131 significant genotype*sex interactions, and *Pappa2* deletion increased cortical area fraction and

132 cortical TMD in both sexes, with no effects on trabecular parameters (Table 3). Although

133 previous work using a different technique (pQCT) found no effect of *Pappa2* deletion on BMD

134 in 4 month old mice [19], this previous analysis did not examine cortical and trabecular bone
135 separately. At 19 weeks (~4.5 months), we observed contrasting effects of *Pappa2* deletion on
136 cortical and trabecular bone that might have been obscured if these two compartments had been
137 analysed together.

138

139 Since PAPP-A2 cleaves IGFBP-5, serum levels of IGFBP-5 were expected to be higher
140 in *Pappa2* deletion mice, and this was observed at 19 and 30 weeks (19 weeks: $F_{1,35} = 8.4$, $P =$
141 0.007 ; 30 weeks: $F_{1,35} = 4.0$, $P = 0.054$; Fig. 1), although the difference was marginally non-
142 significant at 30 weeks. We have previously found serum IGFBP-5 to be elevated in *Pappa2*
143 deletion mice at 6 weeks of age [20]. IGFBP-5 levels were higher in females than in males (19
144 weeks: $F_{1,35} = 9.7$, $P = 0.004$; 30 weeks: $F_{1,35} = 11.9$, $P = 0.002$; Fig. 1), but there was no
145 significant interaction between sex and genotype (19 weeks: $F_{1,35} = 1.26$, $P = 0.27$; 30 weeks:
146 $F_{1,35} = 0.1$, $P = 0.82$; Fig. 1). IGFBP-5 levels were significantly higher at 19 weeks than at 30
147 weeks ($F_{1,74} = 27.0$, $P < 0.0001$; Fig. 1) when analyzing the ages together and including effects of
148 genotype, sex, genotype*sex interaction and age.

149

150 Markers of bone formation (PINP) and bone resorption (TRACP 5b) were lower in
151 *Pappa2* deletion mice (PINP: $F_{1,18} = 6.6$, $P = 0.02$; TRACP 5b: $F_{1,18} = 5.4$, $P = 0.03$; Fig. 2).
152 PINP levels were higher at 6 weeks than 19 weeks ($F_{1,18} = 975.5$, $P < 0.0001$), while TRACP 5b
153 showed the opposite pattern ($F_{1,17} = 117.8$, $P < 0.0001$). However, there was no interaction
154 between age and genotype (PINP: $F_{1,18} = 0.62$, $P = 0.44$; TRACP 5b: $F_{1,17} = 0.1$, $P = 0.83$).

155

156 *Pappa2* deletion reduced markers of bone formation and resorption and the net effect of
157 these changes depended on age. At younger ages, *Pappa2* deletion mice had slightly impaired
158 trabecular parameters, but by 19 weeks of age, female deletion mice had very modest
159 improvement in cortical TMD, and this trait was increased in both sexes by 30 weeks. The
160 increases in cortical area fraction seen in *Pappa2* deletion mice at all ages may reflect subtle
161 changes in bone morphology, as previously described for the mandible and pelvic girdle [17].
162

163 Increased IGFBP-5 concentrations, either at the local level or in circulation, represent a
164 likely mechanism underlying the effects of *Pappa2* deletion. The effects of IGFBP-5 on bone are
165 controversial [11]. IGFBP-5 overexpression reduced BMD in young mice but not in older
166 animals [12,14]. In contrast, daily injections of IGFBP-5 increased BMD in ovariectomized mice
167 [13]. Thus, in healthy young mice, increasing IGFBP-5 may reduce BMD by reducing IGF-I
168 availability, as observed in human children with loss-of-function mutations in *PAPPA2* [3]. In
169 contrast, in older or ovariectomized mice, when bone formation is reduced, an increase in
170 IGFBP-5 may exert beneficial effects through IGF-independent mechanisms. While deletion of
171 *Pappa2*'s paralog, *Pappa*, impaired bone density in mice at 2-12 months of age [26], PAPP-A
172 cleaves IGFBP-4 as well as IGFBP-5, and so it is possible that the beneficial effects of increased
173 IGFBP-5 were outweighed by reduced IGF-I availability due to increased IGFBP-4 and -5 levels.
174

175 In conclusion, the present study shows that, in addition to its effects on the linear growth
176 of bones [17,18], PAPP-A2 also plays sex- and age-specific roles in the regulation of bone mass
177 in mice.
178

179 **Acknowledgements**

180

181 We thank Lisa Wild and Sara Pippard for assistance with the isolation of bones and the IGFBP-5

182 ELISA, and the Animal Care staff at Simon Fraser University for maintaining the animals.

183 Micro-CT analyses were performed in the Centre for High-Throughput Phenogenomics at the

184 University of British Columbia, a facility supported by the Canada Foundation for Innovation,

185 British Columbia Knowledge Development Foundation, and the UBC Faculty of Dentistry.

186

187 **Funding**

188

189 This work was supported by an NSERC (Canada) Discovery Grant to JKC (grant number

190 326791-2011). KIMR was supported by the Merck Canada/ SFU Training of Aboriginal Youth

191 in Biomedical Labs (TAYBL) Program.

192

193 **Declaration of interest**

194

195 The authors have no competing interests.

196

197 **References**

198

199 [1] M.T. Overgaard, H.B. Boldt, L.S. Laursen, L. Sottrup-Jensen, C.A. Conover, C. Oxvig,

200 Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-

201 binding protein-5 proteinase, *J. Biol. Chem.* 276 (2001) 21849–21853.

- 202 [2] R.C. Bunn, J.L. Fowlkes, Insulin-like growth factor binding protein proteolysis, Trends
203 Endocrinol. Metab. 14 (2003) 176–181. doi:10.1016/S1043-2760(03)00049-3.
- 204 [3] A. Dauber, M.T. Munoz-Calvo, V. Barrios, H.M. Domene, S. Klooverpris, C. Serra-Juhe,
205 V. Desikan, J. Pozo, R. Muzumdar, G.A. Martos-Moreno, F. Hawkins, H.G. Jasper, C.A.
206 Conover, J. Frystyk, S. Yakar, V. Hwa, J.A. Chowen, C. Oxvig, R.G. Rosenfeld, L.A.
207 Perez-Jurado, J. Argente, Mutations in pregnancy-associated plasma protein A2 cause
208 short stature due to low IGF-I availability, EMBO Mol. Med. 8 (2016) 363–374.
209 doi:10.15252/emmm.201506106.
- 210 [4] J. Argente, L.A. Pérez-Jurado, History and clinical implications of PAPP-A2 in human
211 growth: When reflecting on idiopathic short stature leads to a specific and new diagnosis,
212 Growth Horm. IGF Res. 40 (2018) 17–19. doi:10.1016/j.ghir.2018.04.001.
- 213 [5] C. Cabrera-Salcedo, T. Mizuno, L. Tyzinski, M. Andrew, A.A. Vinks, J. Frystyk, H.
214 Wasserman, C.M. Gordon, V. Hwa, P. Backeljauw, A. Dauber, Pharmacokinetics of IGF-
215 1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone
216 Density, J. Clin. Endocrinol. Metab. 102 (2017) 4568–4577. doi:10.1210/jc.2017-01411.
- 217 [6] M.T. Muñoz-Calvo, V. Barrios, J. Pozo, J.A. Chowen, G.Á. Martos-Moreno, F. Hawkins,
218 A. Dauber, H.M. Domené, S. Yakar, R.G. Rosenfeld, L.A. Pérez-Jurado, C. Oxvig, J.
219 Frystyk, J. Argente, Treatment with recombinant human insulin-like growth factor-1
220 improves growth in patients with PAPP-A2 deficiency, J. Clin. Endocrinol. Metab. 101
221 (2016) 3879–3883. doi:10.1210/jc.2016-2751.
- 222 [7] F.G. Hawkins-Carranza, M.T. Muñoz-Calvo, G. Martos-Moreno, G. Allo-Miguel, L. Del
223 Río, J. Pozo, J.A. Chowen, L.A. Pérez-Jurado, J. Argente, rhIGF-1 Treatment Increases
224 Bone Mineral Density and Trabecular Bone Structure in Children with PAPP-A2

- 225 Deficiency, *Horm. Res. Paediatr.* 89 (2018) 200–204. doi:10.1159/000486336.
- 226 [8] K.E. Govoni, D.J. Baylink, S. Mohan, The multi-functional role of insulin-like growth
227 factor binding proteins in bone, *Pediatr. Nephrol.* 20 (2005) 261–268.
228 doi:10.1007/s00467-004-1658-y.
- 229 [9] S. Mohan, C. Richman, R.Q. Guo, Y. Amaar, L.R. Donahue, J. Wergedal, D.J. Baylink,
230 Insulin-like growth factor regulates peak bone mineral density in mice by both growth
231 hormone-dependent and -independent mechanisms, *Endocrinology.* 144 (2003) 929–936.
232 doi:10.1210/en.2002-220948.
- 233 [10] S. Yakar, O. Isaksson, Regulation of skeletal growth and mineral acquisition by the
234 GH/IGF-1 axis: Lessons from mouse models, *Growth Horm. IGF Res.* 28 (2016) 26–42.
235 doi:10.1016/j.ghir.2015.09.004.
- 236 [11] A. Mukherjee, P. Rotwein, Insulin-like growth factor binding protein-5 in osteogenesis:
237 Facilitator or inhibitor?, *Growth Horm. IGF Res.* 17 (2007) 179–185.
- 238 [12] D.A.M. Salih, S. Mohan, Y. Kasukawa, G. Tripathi, F.A. Lovett, N.F. Anderson, E.J.
239 Carter, J.E. Wergedal, D.J. Baylink, J.M. Pell, Insulin-like growth factor-binding protein-5
240 induces a gender-related decrease in bone mineral density in transgenic mice,
241 *Endocrinology.* 146 (2005) 931–940. doi:10.1210/en.2004-0816.
- 242 [13] D.L. Andress, IGF-binding protein-5 stimulates osteoblast activity and bone accretion in
243 ovariectomized mice, *Am. J. Physiol. Metab.* 281 (2001) E283–E288.
- 244 [14] R.D. Devlin, Z. Du, V. Buccilli, V. Jorgetti, E. Canalis, Transgenic mice overexpressing
245 insulin-like growth factor binding protein-5 display transiently decreased osteoblastic
246 function and osteopenia, *Endocrinology.* 143 (2002) 3955–3962. doi:10.1210/en.2002-
247 220129.

- 248 [15] S. Mohan, D.J. Baylink, IGF-binding proteins are multifunctional and act via IGF-
249 dependent and -independent mechanisms, *J. Endocrinol.* 175 (2002) 19–31.
250 doi:10.1677/joe.0.1750019.
- 251 [16] N. Miyakoshi, C. Richman, Y. Kasukawa, T.A. Linkhart, D.J. Baylink, S. Mohan,
252 Evidence that IGF-binding protein-5 functions as a growth factor, *J. Clin. Invest.* 107
253 (2001) 73–81. doi:10.1172/JCI10459.
- 254 [17] J.K. Christians, D.R. de Zwaan, S.H.Y. Fung, Pregnancy Associated Plasma Protein A2
255 (PAPP-A2) Affects Bone Size and Shape and Contributes to Natural Variation in
256 Postnatal Growth in Mice, *PLoS One.* 8 (2013) e56260.
257 doi:10.1371/journal.pone.0056260.
- 258 [18] N. Amiri, J.K. Christians, PAPP-A2 expression by osteoblasts is required for normal
259 postnatal growth in mice, *Growth Horm. IGF Res.* 25 (2015) 274–80.
260 doi:10.1016/j.ghir.2015.09.003.
- 261 [19] C.A. Conover, H.B. Boldt, L.K. Bale, K.B. Clifton, J.A. Grell, J.R. Mader, E.J. Mason,
262 D.R. Powell, Pregnancy-Associated Plasma Protein-A2 (PAPP-A2): Tissue Expression
263 and Biological Consequences of Gene Knockout in Mice, *Endocrinology.* 152 (2011)
264 2837–2844.
- 265 [20] J.K. Christians, A.K. Bath, N. Amiri, Pappa2 deletion alters IGFBPs but has little effect
266 on glucose disposal or adiposity, *Growth Horm. IGF Res.* 25 (2015) 232–239.
267 doi:http://dx.doi.org/10.1016/j.ghir.2015.07.001.
- 268 [21] W.G. Beamer, L.R. Donahue, C.J. Rosen, D.J. Baylink, Genetic variability in adult bone
269 density among inbred strains of mice, *Bone.* 18 (1996) 397–403. doi:10.1016/8756-
270 3282(96)00047-6.

- 271 [22] V. Glatt, E. Canalis, L. Stadmeier, M.L. Bouxsein, Age-Related Changes in Trabecular
272 Architecture Differ in Female and Male C57BL/6J Mice, *J. Bone Miner. Res.* 22 (2007)
273 1197–1207. doi:10.1359/jbmr.070507.
- 274 [23] L.M. Franks, J. Payne, The influence of age on reproductive capacity in C57BL mice., *J.*
275 *Reprod. Fertil.* 21 (1970) 563–565.
- 276 [24] M.L. Bouxsein, S.K. Boyd, B.A. Christiansen, R.E. Guldborg, K.J. Jepsen, R. Mueller,
277 Guidelines for Assessment of Bone Microstructure in Rodents Using Micro-Computed
278 Tomography, *J. Bone Miner. Res.* 25 (2010) 1468–1486. doi:10.1002/jbmr.141.
- 279 [25] E.H. Chin, J.K. Christians, When are sex-specific effects really sex-specific?, *J. Dev.*
280 *Orig. Health Dis.* 6 (2015) 438–442. doi:10.1017/S2040174415001348.
- 281 [26] S.J. Tanner, T.E. Hefferan, C.J. Rosen, C.A. Conover, Impact of pregnancy-associated
282 plasma protein-A deletion on the adult murine skeleton, *J. Bone Miner. Res.* 23 (2008)
283 655–662.
- 284




Figure 1. Effects of *Pappa2* deletion on serum IGFBP-5 levels at 19 and 30 weeks of age (black bars: *Pappa2* deletion mice; grey bars: controls). Values are least squares means \pm standard error from general linear models including effects of genotype, sex, and the genotype*sex interaction. Data were log-transformed prior to analyses and back-transformed for graphical presentation. Sample sizes are shown above the x-axis.




Figure 2. Effects of *Pappa2* deletion on serum PINP and TRACP 5b levels in females at 6 and 19 weeks of age (black bars: *Pappa2* deletion mice; grey bars: controls). Levels were measured in the same individuals at two different ages and values are least squares means \pm standard error from a repeated measures analyses including effects of genotype, age, and the genotype*age interaction. Data were log-transformed prior to analyses and back-transformed for graphical presentation. N = 10 females per genotype.

Table 1. Bone parameters at 10 weeks of age. Values are least squares means \pm standard error from a general linear model including effects of genotype, sex, and the genotype*sex interaction. Traits where the effect of genotype is significant are shown in bold.

	Females		Males		Genotype*sex		Genotype		Sex	
	<i>Pappa2</i> ^{KO/KO}	<i>Pappa2</i> ^{wt/wt}	<i>Pappa2</i> ^{KO/KO}	<i>Pappa2</i> ^{wt/wt}	F _{1,27}	P	F _{1,27}	P	F _{1,27}	P
Sample size	9	6	9	7						
Mass at cull (g)	16.3 \pm 0.5	19.0 \pm 0.6	22.2 \pm 0.5	24.5 \pm 0.6	0.1	0.73	22.5	0.0001	115.3	0.0001
Femur length (mm)	13.9 \pm 0.1	14.3 \pm 0.1	14.5 \pm 0.1	14.8 \pm 0.1	0.3	0.58	9.2	0.005	21.6	0.0001
Trabecular										
TV (mm ³)	1.000 \pm 0.035	1.208 \pm 0.043	1.345 \pm 0.035	1.572 \pm 0.039	0.0	0.81	32.8	0.0001	87.2	0.0001
BV (mm ³)	0.055 \pm 0.012	0.057 \pm 0.014	0.147 \pm 0.012	0.185 \pm 0.013	2.0	0.17	2.6	0.12	76.5	0.0001
BV/TV (%)	5.4 \pm 0.6	4.7 \pm 0.8	10.9 \pm 0.6	11.6 \pm 0.7	1.0	0.34	0.0	0.98	76.4	0.0001
Tb.N (mm ⁻¹)	4.3 \pm 0.2	4.1 \pm 0.2	5.3 \pm 0.2	5.1 \pm 0.2	0.1	0.76	1.0	0.32	36.5	0.0001
Tb.Th (μ m)	32 \pm 1	33 \pm 1	37 \pm 1	40 \pm 1	2.6	0.12	5.1	0.03	51.6	0.0001
Tb.Sp (mm)	0.24 \pm 0.01	0.24 \pm 0.01	0.18 \pm 0.01	0.19 \pm 0.01	0.0	0.94	1.2	0.29	36.1	0.0001
Cortical										
Tt.Ar (mm ²)	1.20 \pm 0.04	1.42 \pm 0.04	1.49 \pm 0.04	1.72 \pm 0.04	0.0	0.84	35.2	0.0001	59.0	0.0001
Ct.Ar (mm ²)	0.54 \pm 0.02	0.58 \pm 0.02	0.66 \pm 0.02	0.73 \pm 0.02	0.8	0.39	8.1	0.008	47.3	0.0001
Ct.Ar/Tt.Ar (%)	45 \pm 1	41 \pm 1	44 \pm 1	42 \pm 1	4.2	0.051	26.8	0.0001	1.4	0.25
Ct.Th (μ m)	155 \pm 3	149 \pm 4	167 \pm 3	166 \pm 3	0.9	0.35	1.1	0.31	21.7	0.0001
Ct.Po (%)	8.1 \pm 0.2	8.4 \pm 0.3	7.7 \pm 0.2	8.0 \pm 0.3	0.0	0.91	1.5	0.23	2.9	0.10
TMD (mg HA/cm ³)	1153 \pm 7	1158 \pm 8	1140 \pm 7	1123 \pm 8	2.4	0.14	0.7	0.40	11.0	0.003

Table 2. Bone parameters at 19 weeks of age. Values are least squares means \pm standard error from a general linear model including effects of genotype, sex, and the genotype*sex interaction. Where the genotype*sex interaction is significant, the difference between genotypes has been tested within each sex. Traits where the effect of genotype is significant are shown in bold. In some cases, the genotype*sex interaction is significant and the effect of genotype is significant within both sexes, indicating that the magnitude of the effect differs between the sexes.

	Females		Males		Genotype*sex		Genotype		Sex	
	<i>Pappa2^{KO/KO}</i>	<i>Pappa2^{fl/fl}</i>	<i>Pappa2^{KO/KO}</i>	<i>Pappa2^{fl/fl}</i>	F _{1,35}	P	F _{1,35}	P	F _{1,35}	P
Sample size	10	14	6	9						
Mass at cull (g)	18.8 \pm 0.6	21.1 \pm 0.4	23.8 \pm 0.9	26.7 \pm 0.6	0.2	0.64	14.9	0.0008	61.8	0.0001
Femur length (mm)	14.2 \pm 0.1	14.4 \pm 0.1	14.4 \pm 0.1	14.9 \pm 0.1	4.7	0.037	18.3	0.0001	14.2	0.0006
Trabecular										
TV (mm ³)	0.771 \pm 0.040	1.063 \pm 0.034	1.110 \pm 0.051	1.662 \pm 0.042	9.5	0.004	100.4	0.0001	123.6	0.0001
BV (mm ³)	0.010 \pm 0.006	0.015 \pm 0.005	0.059 \pm 0.007	0.122 \pm 0.006	20.5	0.0001	28.7	0.0001	149.7	0.0001
BV/TV (%)	1.3 \pm 0.3	1.4 \pm 0.3	5.3 \pm 0.4	7.3 \pm 0.4	6.5	0.015	7.8	0.009	183.7	0.0001
Tb.N (mm ⁻¹)	2.8 \pm 0.1	2.7 \pm 0.1	3.9 \pm 0.1	3.7 \pm 0.1	0.3	0.56	2.0	0.17	87.6	0.0001
Tb.Th (μ m)	27 \pm 2	34 \pm 2	40 \pm 3	43 \pm 3	0.4	0.54	3.6	0.07	16.0	0.0003
Tb.Sp (mm)	0.36 \pm 0.01	0.37 \pm 0.01	0.26 \pm 0.01	0.27 \pm 0.01	0.1	0.83	0.9	0.36	70.0	0.0001
Cortical										
Tt.Ar (mm ²)	1.34 \pm 0.03	1.64 \pm 0.03	1.77 \pm 0.04	2.17 \pm 0.04	1.6	0.22	94.4	0.0001	178.6	0.0001
Ct.Ar (mm ²)	0.69 \pm 0.01	0.75 \pm 0.01	0.79 \pm 0.02	0.93 \pm 0.01	7.9	0.008	48.5	0.0001	92.8	0.0001
Ct.Ar/Tt.Ar (%)	52 \pm 1	46 \pm 1	45 \pm 1	43 \pm 1	11.7	0.002	43.3	0.0001	68.2	0.0001
Ct.Th (μ m)	192 \pm 2	183 \pm 2	184 \pm 3	192 \pm 3	10.5	0.003	0.0	0.89	0.1	0.82
Ct.Po (%)	5.6 \pm 0.2	5.9 \pm 0.2	6.2 \pm 0.2	5.6 \pm 0.2	5.1	0.03	0.8	0.38	0.5	0.48
TMD (mg HA/cm ³)	1257 \pm 6	1241 \pm 5	1215 \pm 7	1222 \pm 6	3.9	0.06	0.6	0.44	27.5	0.0001

Table 3. Bone parameters at 30 weeks of age. Values are least squares means \pm standard error from a general linear model including effects of genotype, sex, and the genotype*sex interaction. Traits where the effect of genotype is significant are shown in bold.

	Females		Males		Genotype*sex		Genotype		Sex	
	<i>Pappa2</i> ^{KO/KO}	<i>Pappa2</i> ^{fl/fl}	<i>Pappa2</i> ^{KO/KO}	<i>Pappa2</i> ^{fl/fl}	F _{1,36}	P	F _{1,36}	P	F _{1,36}	P
Sample size	10	7	16	7						
Mass at cull (g)	22.4 \pm 0.8	25.4 \pm 0.9	28.1 \pm 0.6	30.9 \pm 0.9	0.0	0.95	13.6	0.0008	49.1	0.0001
Femur length (mm)	14.6 \pm 0.1	14.9 \pm 0.1	14.6 \pm 0.1	15.0 \pm 0.1	1.0	0.32	13.0	0.0009	0.1	0.72
Trabecular										
TV (mm ³)	1.227 \pm 0.063	1.503 \pm 0.075	1.673 \pm 0.050	2.039 \pm 0.075	0.5	0.51	23.3	0.0001	54.5	0.0001
BV (mm ³)	0.040 \pm 0.017	0.052 \pm 0.020	0.197 \pm 0.013	0.215 \pm 0.020	0.0	0.87	0.7	0.40	80.3	0.0001
BV/TV (%)	3.3 \pm 0.7	3.4 \pm 0.9	11.6 \pm 0.6	10.2 \pm 0.9	0.9	0.34	0.6	0.46	91.0	0.0001
Tb.N (mm ⁻¹)	2.7 \pm 0.1	2.6 \pm 0.1	3.8 \pm 0.1	3.9 \pm 0.1	0.2	0.68	0.0	0.97	165.8	0.0001
Tb.Th (μ m)	44 \pm 2	45 \pm 2	49 \pm 1	44 \pm 2	3.4	0.07	1.3	0.27	1.45	0.24
Tb.Sp (mm)	0.38 \pm 0.01	0.38 \pm 0.01	0.25 \pm 0.01	0.25 \pm 0.01	0.0	0.88	0.0	0.98	188.7	0.0001
Cortical										
Tt.Ar (mm ²)	1.40 \pm 0.05	1.74 \pm 0.06	1.94 \pm 0.04	2.27 \pm 0.06	0.0	0.87	37.1	0.0001	96.9	0.0001
Ct.Ar (mm ²)	0.73 \pm 0.02	0.82 \pm 0.02	0.82 \pm 0.01	0.90 \pm 0.02	0.0	0.86	19.0	0.0001	20.8	0.0001
Ct.Ar/Tt.Ar (%)	52 \pm 1	47 \pm 1	42 \pm 1	40 \pm 1	2.4	0.13	18.1	0.0001	92.9	0.0001
Ct.Th (μ m)	198 \pm 3	194 \pm 4	178 \pm 3	173 \pm 4	0.0	0.92	1.4	0.25	30.0	0.0001
Ct.Po (%)	5.3 \pm 0.1	5.6 \pm 0.2	6.3 \pm 0.2	6.6 \pm 0.2	0.0	0.91	1.6	0.21	22.6	0.0001
TMD (mg HA/cm ³)	1266 \pm 6	1257 \pm 7	1217 \pm 5	1196 \pm 7	0.9	0.34	6.0	0.02	79.7	0.0001